Aldafermin

Aldafermin
Clinical data
Other names	NGM282; NGM-282
Legal status
Legal status	Investigational;
Identifiers
CAS Number	1616639-03-2;
IUPHAR/BPS	11546;
UNII	IK9NYN31ZM;
KEGG	D11734;
ChEMBL	ChEMBL4298055;
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).;
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).

Aldafermin is a fibroblast growth factor 19 (FGF19) analogue developed for non-alcoholic steatohepatitis.^[1]^[2]^[3]^[4]

References

^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.